Target Audience

Pharmaceutical researchers, drug development scientists

Challenge

Traditional drug discovery takes 10+ years and costs over $2 billion. Idiopathic pulmonary fibrosis affects approximately 5 million people worldwide with a median survival of just 3-4 years. Current treatments can only slow disease progression but cannot stop or reverse it.

Solution Approach

Insilico used its generative AI platform Pharma.AI, combining PandaOmics for target discovery and Chemistry42 for molecular design, to identify TNIK as a novel target and design a small molecule inhibitor. The AI-powered approach compressed the typical drug discovery timeline from 10+ years to under 30 months.

Value Add

The Phase 2a trial (71 patients across 21 sites) showed significant improvement over the placebo group. Results were published in Nature Medicine in June 2025, representing the first peer-reviewed Phase 2a success for a fully AI-generated drug with an AI-discovered target.

References

Insilico Medicine

Read more here: https://www.prnewswire.com/news-releases/insilico-medicine-announces-positive-topline-results-of-ism001-055-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-developed-using-generative-ai-302302583.html